IN8BIO, INC. Stock-Based Compensation
IN8BIO, INC. (INAB) reported Stock-Based Compensation of $753.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- IN8BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $352.00K, a 63.14% decline year-over-year.
- IN8BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $401.00K, a 51.74% decline year-over-year.
- IN8BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $711.00K, a 13.82% decline year-over-year.
- IN8BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $692.00K, a 60.77% decline year-over-year.
- IN8BIO, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $3.19M, a 36.22% decline from fiscal 2024.
- IN8BIO, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $5.00M, a 14.42% increase from fiscal 2023.
- IN8BIO, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $4.37M, a 26.05% increase from fiscal 2022.
- IN8BIO, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $3.47M, a 57.95% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $352.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $753.00K 10-Q · filed 2026-08-06 | $1.46M derived: sum of 3 quarters · filed 2026-08-06 | $2.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $401.00K 10-Q · filed 2026-05-07 | $1.11M derived: sum of 2 quarters · filed 2026-05-07 | $1.80M derived: sum of 3 quarters · filed 2026-05-07 | $2.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $711.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.40M derived: sum of 2 quarters · filed 2026-03-12 | $2.36M derived: sum of 3 quarters · filed 2026-08-06 | $3.19M 10-K · filed 2026-03-12 |
| 2025-09-30 | $692.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.65M derived: sum of 2 quarters · filed 2026-08-06 | $2.48M 10-Q · filed 2025-11-06 | $3.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $955.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.79M 10-Q · filed 2026-08-06 | $2.61M derived: sum of 3 quarters · filed 2026-08-06 | $4.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $831.00K 10-Q · filed 2026-05-07 | $1.66M derived: sum of 2 quarters · filed 2026-05-07 | $3.42M derived: sum of 3 quarters · filed 2026-05-07 | $4.59M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $825.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.59M derived: sum of 2 quarters · filed 2026-03-12 | $3.76M derived: sum of 3 quarters · filed 2026-03-12 | $5.00M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.94M derived: sum of 2 quarters · filed 2025-11-06 | $4.17M 10-Q · filed 2025-11-06 | $5.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.41M 10-Q · filed 2025-08-07 | $3.66M derived: sum of 3 quarters · filed 2025-08-07 | $4.90M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.24M 10-Q · filed 2025-05-07 | $2.49M derived: sum of 2 quarters · filed 2025-05-07 | $3.73M derived: sum of 3 quarters · filed 2025-05-07 | $4.75M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.49M derived: sum of 2 quarters · filed 2025-03-13 | $3.51M derived: sum of 3 quarters · filed 2025-03-13 | $4.37M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.26M derived: sum of 2 quarters · filed 2024-11-12 | $3.12M 10-Q · filed 2024-11-12 | $4.04M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.88M 10-Q · filed 2024-08-08 | $2.80M derived: sum of 3 quarters · filed 2024-08-08 | $3.70M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $859.00K 10-Q · filed 2024-05-09 | $1.78M derived: sum of 2 quarters · filed 2024-05-09 | $2.68M derived: sum of 3 quarters · filed 2024-05-09 | $3.56M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $922.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.82M derived: sum of 2 quarters · filed 2024-03-14 | $2.70M derived: sum of 3 quarters · filed 2024-03-14 | $3.47M 10-K · filed 2024-03-14 |
| 2022-09-30 | $897.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.78M derived: sum of 2 quarters · filed 2023-11-09 | $2.54M 10-Q · filed 2023-11-09 | $3.51M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $884.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.65M 10-Q · filed 2023-08-10 | $2.61M derived: sum of 3 quarters · filed 2023-08-10 | $3.09M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $764.00K 10-Q · filed 2023-05-12 | $1.73M derived: sum of 2 quarters · filed 2023-05-12 | $2.21M derived: sum of 3 quarters · filed 2023-05-12 | $2.60M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $965.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.44M derived: sum of 2 quarters · filed 2023-03-30 | $1.83M derived: sum of 3 quarters · filed 2023-03-30 | $2.19M 10-K · filed 2023-03-30 |
| 2021-09-30 | $477.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $869.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.23M 10-Q · filed 2022-11-10 | $1.53M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $392.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $753.00K 10-Q · filed 2022-08-12 | $1.06M derived: sum of 3 quarters · filed 2022-08-12 | $1.07M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $361.00K 10-Q · filed 2022-05-12 | $664.00K derived: sum of 2 quarters · filed 2022-05-12 | $680.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $319.00K derived: sum of 2 quarters · filed 2022-03-17 | $357.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $54.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $38.00K 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |